Brief: Syros Receives FDA Orphan Drug Designation For Tamibarotene For The Treatment Of Mds
02/02/2022 21:46
Feb 2 (Reuters) - Syros Pharmaceuticals Inc SYRS.O :
* SYROS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
TAMIBAROTENE FOR
THE TREATMENT OF MDS
Source text for Eikon: ID:nBw9G6LQYa
Further company coverage: SYRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial